Sanford C. Bernstein Has Lowered Expectations for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price

Key Points

• Sanford C. Bernstein slightly cut its price target for Regeneron to $921 (from $925) but kept an "outperform" rating, implying about a 20.8% upside from the prior close.
• Analyst consensus is a Moderate Buy with an average price target of $810.78, while several firms recently issued buy/outperform ratings and higher targets in the $860–$875 range.
• Regeneron beat quarterly estimates with EPS of $11.44 (vs. $10.74 expected) and revenue of $3.88B, and the stock trades around a market cap of roughly $80.6B (52‑week range $476.49–$821.11).

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) had its price objective decreased by investment analysts at Sanford C. Bernstein from $925.00 to $921.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage presently has an "outperform" rating on the biopharmaceutical company's stock. Sanford C. Bernstein's price target indicates a potential upside of 20.82% from the company's previous close.

Other research analysts have also recently issued reports about the company. Zacks Research cut Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Friday, February 6th. Bank of America raised Regeneron Pharmaceuticals from an "underperform" rating to a "buy" rating and lifted their price objective for the company from $627.00 to $860.00 in a report on Wednesday, January 7th. Evercore lifted their price objective on Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the company an "outperform" rating in a report on Thursday, January 22nd. Piper Sandler began coverage on Regeneron Pharmaceuticals in a report on Tuesday, March 31st. They issued an "overweight" rating and a $875.00 price target for the company. Finally, Oppenheimer reaffirmed an "outperform" rating and issued a $865.00 price target (up from $750.00) on shares of Regeneron Pharmaceuticals in a report on Monday, February 2nd. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $810.78.

Regeneron Pharmaceuticals Stock Up 0.3%

Shares of NASDAQ REGN opened at $762.31 on Wednesday. The stock has a market cap of $80.59 billion, a PE ratio of 18.40, a PEG ratio of 2.02 and a beta of 0.40. The business has a fifty day moving average of $766.41 and a two-hundred day moving average of $717.18. Regeneron Pharmaceuticals has a 52-week low of $476.49 and a 52-week high of $821.11. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.39 and a current ratio of 4.13.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $10.74 by $0.70. The company had revenue of $3.88 billion during the quarter, compared to analysts' expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The business's revenue was up 2.5% on a year-over-year basis. During the same period last year, the business earned $12.07 earnings per share. As a group, equities research analysts expect that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current fiscal year.

Insider Activity at Regeneron Pharmaceuticals

In related news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $778.53, for a total value of $77,853.00. Following the completion of the transaction, the director directly owned 17,803 shares of the company's stock, valued at $13,860,169.59. The trade was a 0.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Huda Y. Zoghbi sold 1,638 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $781.33, for a total value of $1,279,818.54. Following the completion of the transaction, the director directly owned 1,703 shares of the company's stock, valued at $1,330,604.99. This represents a 49.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 3,774 shares of company stock valued at $2,942,738 over the last ninety days. 7.02% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Purpose Unlimited Inc. acquired a new position in Regeneron Pharmaceuticals during the 4th quarter valued at about $87,000. Rockefeller Capital Management L.P. lifted its position in Regeneron Pharmaceuticals by 4.7% during the 4th quarter. Rockefeller Capital Management L.P. now owns 27,053 shares of the biopharmaceutical company's stock valued at $20,882,000 after purchasing an additional 1,211 shares during the period. World Investment Advisors lifted its position in Regeneron Pharmaceuticals by 56.5% during the 4th quarter. World Investment Advisors now owns 798 shares of the biopharmaceutical company's stock valued at $616,000 after purchasing an additional 288 shares during the period. PeakShares LLC acquired a new position in Regeneron Pharmaceuticals during the 4th quarter valued at about $1,102,000. Finally, Pure Financial Advisors LLC lifted its position in Regeneron Pharmaceuticals by 35.4% during the 4th quarter. Pure Financial Advisors LLC now owns 497 shares of the biopharmaceutical company's stock valued at $384,000 after purchasing an additional 130 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc NASDAQ: REGN is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.